Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,078 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Stage Solid Tumors Clear all

Conditions: Solid Tumor, Adult
Interventions: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody; Drug · Biological
Lead sponsor: Linnaeus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more

Conditions: Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms
Interventions: BI 836880, Ezabenlimab; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Beverly Hills, California • Atlanta, Georgia + 3 more

Conditions: Solid Tumours
Interventions: SB-715992, carboplatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: alvocidib, irinotecan hydrochloride; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
Interventions: Pembrolizumab, Lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Solid Tumor
Interventions: BHV-1530, Cemiplimab; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 17
States / cities: Newport Beach, California • Denver, Colorado • Lake Mary, Florida + 14 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: recombinant interferon alfa, cisplatin, gemcitabine hydrochloride, hyperthermia treatment; Biological · Drug · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: BMS-906024; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 3 more

Conditions: Advanced Solid Tumor
Interventions: BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more

Conditions: Metastatic Cancer, Solid Tumor, Lymphoma
Interventions: Sym023; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas

Conditions: Solid Tumors
Interventions: Iso-Fludelone; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Cancers
Interventions: Azacitidine, Lenalidomide, Grifola Frondosa; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 13 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Select Advanced Solid Tumors
Interventions: IMC-C103C, Atezolizumab; Drug
Lead sponsor: Immunocore Ltd; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more

Conditions: Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
Interventions: STP705; Drug
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Scottsdale, Arizona • Los Angeles, California • Louisville, Kentucky + 1 more

Conditions: cMET-dysregulated Advanced Solid Tumors
Interventions: INC280, Midazolam, Caffeine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia • St Louis, Missouri

Conditions: Advanced Solid Tumor
Interventions: Hyperpolarized 13C-Pyruvate, Magnetic Resonance Imaging (MRI), 13C,15N-Urea; Drug · Procedure
Lead sponsor: Robert Bok, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Solid Tumors
Interventions: BKM120 days 1 - 21 plus paclitaxel + carboplatin, BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin, BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1), BKM120, Paclitaxel + Carboplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer, Non-Small Cell Lung Cancer
Interventions: Dasatinib, Erlotinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumor
Interventions: XTX301; Drug
Lead sponsor: Xilio Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Sacramento, California • New Haven, Connecticut • Saint Louis Park, Minnesota + 9 more

Conditions: Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
Interventions: ITIL-306; Biological
Lead sponsor: Instil Bio; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: St Louis, Missouri • New York, New York

Conditions: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
Interventions: Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Baltimore, Maryland • New York, New York + 3 more

Conditions: Solid Tumors
Interventions: PM060184; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Advanced Solid Tumors, Lymphoma
Interventions: IXAZOMIB; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced Solid Malignancies
Interventions: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 11
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Search by objective public record fields.

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

Flavopiridol and Irinotecan in Treating Patients With Advanced Solid Tumors

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors

Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

XTX301 in Patients With Advanced Solid Tumors

ITIL-306 in Advanced Solid Tumors

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Study of PM060184 in Patients With Advanced Solid Tumors

Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies